The global alveolar capillary dysplasia treatment market size was valued at USD 21.14 million in 2025 and is expected to reach USD 32.93 million by 2033, at a CAGR of 5.70% during the forecast period
The market growth is largely fueled by increasing awareness of ACD among healthcare professionals and patients, advancements in diagnostic techniques such as genetic testing, and ongoing research in rare-disease therapies. These developments are improving early diagnosis and opening potential avenues for treatment
Furthermore, rising investment in rare disease research, growing focus on precision medicine, and the adoption of novel therapeutic approaches are positioning ACD treatments as increasingly viable options for affected patients. These converging factors are accelerating the uptake of treatment solutions, thereby significantly boosting the industry's growth